FREMONT, Calif., Sept. 22, 2016 /PRNewswire/ -- Ardelyx, Inc.
(NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused
on gastrointestinal and cardio-renal diseases, today announced that
Mark Kaufmann, Chief Financial
Officer, will present an overview of the Company during the
Ladenburg Thalmann 2016 Healthcare Conference at 9:30 a.m. Eastern Time on Tuesday, September 27, 2016 at the Sofitel New
York Hotel in New York, NY.
Paul Korner, MD, MBA, the Company's
Executive Vice President and Chief Medical Officer, will also be in
attendance.
About Ardelyx, Inc.
Ardelyx is a clinical-stage biopharmaceutical company focused on
the discovery, development and commercialization of innovative,
minimally-systemic, small molecule therapeutics that work
exclusively in the gastrointestinal (GI) tract to treat GI and
cardio-renal diseases. Ardelyx has developed a proprietary drug
discovery and design platform enabling it, in a rapid and
cost-efficient manner, to discover and design novel drug
candidates. Utilizing this platform, Ardelyx has discovered and
designed tenapanor, which it is evaluating for the treatment of
irritable bowel syndrome with constipation (IBS-C) and for the
treatment of hyperphosphatemia in patients with end-stage renal
disease (ESRD) on dialysis. In addition to tenapanor, Ardelyx is
developing RDX227675, a non-absorbed polymer for the treatment of
hyperkalemia, or high potassium, a problem prevalent in patients
with kidney and heart disease. Ardelyx is also advancing
several research programs focused in GI and cardio-renal diseases.
Ardelyx is located in Fremont,
California. For more information, please visit Ardelyx's
website at www.ardelyx.com.
Logo - http://photos.prnewswire.com/prnh/20140619/119451
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/ardelyx-to-present-at-ladenburg-thalmann-2016-healthcare-conference-300332792.html
SOURCE Ardelyx